Inhibrx Biosciences (INBX) to Post Earnings on Wednesday

Inhibrx Biosciences (NASDAQ:INBX) is anticipated to post its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($2.28) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Inhibrx Biosciences (NASDAQ:INBX) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.47). On average, analysts expect Inhibrx Biosciences to post $-10 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Inhibrx Biosciences Trading Up 1.7%

Shares of NASDAQ:INBX opened at $84.17 on Wednesday. Inhibrx Biosciences has a 52 week low of $20.55 and a 52 week high of $155.29. The company’s 50 day moving average is $91.87 and its two-hundred day moving average is $87.63. The company has a market cap of $1.23 billion, a PE ratio of -10.03 and a beta of 3.51. The company has a current ratio of 6.46, a quick ratio of 6.46 and a debt-to-equity ratio of 12.58.

Institutional Trading of Inhibrx Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Inhibrx Biosciences in the 1st quarter valued at about $27,000. Persistent Asset Partners Ltd purchased a new position in Inhibrx Biosciences during the 4th quarter worth approximately $27,000. Public Employees Retirement System of Ohio acquired a new position in Inhibrx Biosciences during the third quarter worth approximately $40,000. BNP Paribas Financial Markets increased its position in Inhibrx Biosciences by 71.9% during the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock worth $64,000 after buying an additional 789 shares during the period. Finally, Daiwa Securities Group Inc. purchased a new position in Inhibrx Biosciences during the fourth quarter worth about $66,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Zacks Research raised Inhibrx Biosciences to a “hold” rating in a report on Thursday, April 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibrx Biosciences in a research report on Tuesday, June 16th. Stifel Nicolaus initiated coverage on Inhibrx Biosciences in a report on Wednesday, April 8th. They issued a “buy” rating and a $150.00 price objective on the stock. Lifesci Capital raised Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Wall Street Zen cut Inhibrx Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $150.00.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.